MK 8723

Drug Profile

MK 8723

Alternative Names: MK-8723

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antithrombotics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Immune thrombocytopenic purpura

Most Recent Events

  • 11 Oct 2013 Preclinical trials in Immune thrombocytopenic purpura in USA (IV)
  • 11 Oct 2013 Merck plans a phase I trial in Immune thrombocytopenic purpura in Australia and Israel (NCT01963260)
  • 01 Oct 2013 Phase-I clinical trials in Immune thrombocytopenic purpura in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top